文献速递痛风与晶体性关节病类风湿关节炎其他结缔组织病

焦磷酸钙沉积病与相关共病:美国退伍军人全国横断面研究

Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2017-08-08

该研究利用美国退伍军人事务部企业数据仓库,纳入2010至2014年就诊的CPDD患者25157例,按年龄和性别匹配无CPDD对照,采用多因素分析比较共病、物质使用、药物暴露和关节置换的患病率与比值比。结果显示CPDD点患病率为5.2/1000,与甲状旁腺功能亢进、痛风、骨关节炎、类风湿关节炎和血色病呈最强正相关,并提示与类风湿关节炎、低镁血症和骨质疏松的正相关及与质子泵抑制剂和袢利尿剂的负相关。

要点

  • CPDD患者中甲状旁腺功能亢进、痛风、骨关节炎、类风湿关节炎和血色病与CPDD的正相关最强。
  • 低镁血症、骨质疏松、慢性肾病和钙剂补充也与CPDD呈正相关。
  • 质子泵抑制剂和袢利尿剂与CPDD呈负相关,提示潜在新关联。

核心结论

  • 在大样本全国数据集中确认了CPDD的已知关联,并为类风湿关节炎、低镁血症和骨质疏松的正相关提供支持,提示常用药物可能存在新的负相关。

研究设计与样本

  • 基于美国退伍军人事务部企业数据仓库,纳入2010至2014年就诊的CPDD患者25157例,按年龄和性别匹配无CPDD对照,采用多因素分析比较共病、物质使用、药物暴露和关节置换的患病率与比值比。

主要发现

  • CPDD点患病率为5.2/1000,患者平均年龄68.1±12.3岁,95%为男性。
  • 与CPDD正相关最强的因素为甲状旁腺功能亢进(OR 3.35 [95%CI 2.96-3.79])、痛风(OR 2.82 [95%CI 2.69-2.95])、骨关节炎(OR 2.26 [95%CI 2.15-2.37])、类风湿关节炎(OR 1.88 [95%CI 1.74-2.03])和血色病(OR 1.87 [95%CI 1.57-2.24])。
  • 骨质疏松(OR 1.26 [95%CI 1.16-1.36])、低镁血症(OR 1.23 [95%CI 1.16-1.30])、慢性肾病(OR 1.12 [95%CI 1.07-1.18])和钙剂补充(OR 1.15 [95%CI 1.06-1.24)也与CPDD呈正相关。
  • 质子泵抑制剂(OR 0.58 [95%CI 0.55-0.60])和袢利尿剂(OR 0.80 [95%CI 0.76-0.84])与CPDD呈负相关。

关键数值与推荐

  • CPDD定义为2010至2014年间任何退伍军人医疗中心就诊且具有国际疾病分类第九版CPDD编码的患者。
  • 对照为按年龄和性别匹配的无CPDD患者。

临床怎么用

  • 对CPDD患者应评估甲状旁腺功能亢进、痛风、骨关节炎、类风湿关节炎和血色病等共病。
  • 低镁血症、骨质疏松、慢性肾病和钙剂补充也与CPDD相关,临床管理中可予以关注。
  • 质子泵抑制剂和袢利尿剂与CPDD的负相关需进一步研究验证,目前不宜据此改变用药。

局限性

  • 本研究为横断面设计,无法推断因果关系。
  • 研究人群以男性退伍军人为主(95%为男性),结果外推需谨慎。
  • CPDD基于ICD-9编码定义,可能存在编码偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Calcium pyrophosphate deposition disease (CPDD) is a common cause of acute and chronic arthritis, yet there are few large epidemiologic studies of CPDD. We sought to characterize CPDD in the national Veterans Affairs (VA) population. METHODS: Using data from the Department of VA Corporate Data Warehouse, patients with International Classification of Diseases, Ninth Revision, codes for CPDD seen at any VA medical center from 2010 through 2014 were matched by age and sex with control patients without CPDD. We used multivariate analysis to compare the prevalence and odds ratios (ORs) of various comorbidities, substance use, medication exposures, and arthroplasties among patients with and without CPDD. RESULTS: We identified 25,157 patients with CPDD, yielding a point prevalence of 5.2 per 1,000. The mean ± SD age was 68.1 ± 12.3 years, and 95% were male. The strongest positive associations with CPDD were hyperparathyroidism (OR 3.35 [95% confidence interval (95% CI) 2.96-3.79]), gout (OR 2.82 [95% CI 2.69-2.95]), osteoarthritis (OR 2.26 [95% CI 2.15-2.37]), rheumatoid arthritis (OR 1.88 [95% CI 1.74-2.03]), and hemochromatosis (OR 1.87 [95% CI 1.57-2.24]). Positive associations were also seen with higher odds for osteoporosis (OR 1.26 [95% CI 1.16-1.36]), hypomagnesemia (OR 1.23 [95% CI 1.16-1.30]), chronic kidney disease (OR 1.12 [95% CI 1.07-1.18]), and calcium supplementation (OR 1.15 [95% CI 1.06-1.24). Negative associations were seen with proton-pump inhibitors (OR 0.58 [95% CI 0.55-0.60]) and loop diuretics (OR 0.80 [95% CI 0.76-0.84]). CONCLUSION: Using a large national data set, we confirmed known associations with CPDD, provided support for positive associations with rheumatoid arthritis, hypomagnesemia, and osteoporosis, and suggested potential novel negative associations with commonly used medications.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Kleiber Balderrama C, Rosenthal AK, Lans D, et al. Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans. Arthritis Care Res (Hoboken). 2017. PMID: 27898996. doi:10.1002/acr.23160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。